Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

Weisel, Katja; Ludwig, Heinz; Rieth, Achim; Lebioda, Andrea; Goldschmidt, Hartmut

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2020-11-02T07:48:34Z
dc.date.available	2020-11-02T07:48:34Z
dc.date.issued	2020
dc.identifier.issn	1573-2649
dc.identifier.uri	http://hdl.handle.net/10900/108829
dc.language.iso	en	de_DE
dc.publisher	Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s11136-019-02307-5	de_DE
dc.subject.ddc	300	de_DE
dc.subject.ddc	610	de_DE
dc.title	Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200715072417_02157
utue.publikation.seiten	69-79	de_DE
utue.personen.roh	Weisel, Katja
utue.personen.roh	Ludwig, Heinz
utue.personen.roh	Rieth, Achim
utue.personen.roh	Lebioda, Andrea
utue.personen.roh	Goldschmidt, Hartmut
dcterms.isPartOf.ZSTitelID	Quality of Life Research	de_DE
dcterms.isPartOf.ZS-Issue	1	de_DE
dcterms.isPartOf.ZS-Volume	29	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE